Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas

Medical Oncology

Volumn 32, Issue 3, 2015, Pages

  Cheng, Shaomei ^a   Guo, Jingyan ^a   Yang, Qing ^a   Yang, Xiangshan ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

CCL19 CCR7; CrkL; EMT; EOC

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CRK LIKE PROTEIN; GELATINASE B; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PROTEIN KINASE B; REV PROTEIN; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; CCL19 PROTEIN, HUMAN; CCR7 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MIDDLE AGED; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING; WOUND CLOSURE; CELL MOTION; FEMALE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL19; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, CCR7; SIGNAL TRANSDUCTION;

EID: 84961292025     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0494-1     Document Type: Article

References (25)

1. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053–64.
2. Coleman RL, Monk BJ, Sood AK, et al. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013;10:211–24.
3. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–8.
4. Gurung A, Hung T, Morin J, et al. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology. 2013;62:59–70.
5. Sriram G, Birge RB. Emerging roles for crk in human cancer. Genes Cancer. 2010;1:1132–9.
6. Guo C, Liu S, Sun MZ. The role of CT10 regulation of kinase-like in cancer. Future Oncol. 2014;10:2687–97.
7. Kumar S, Fajardo JE, Birge RB, et al. Crk at the quarter century mark: perspectives in signaling and cancer. J Cell Biochem. 2014;115:819–25.
8. Han B, Luan L, Xu Z, et al. Clinical significance and biological roles of CRKL in human bladder carcinoma. Tumour Biol. 2014;35:4101–6.
9. Evren S, Ma XZ, Sakac D, et al. SHP-1 protein tyrosine phosphatase associates with the adaptor protein CrkL. Exp Hematol. 2012;40:1055–9.
10. Birge RB, Kalodimos C, Inagaki F, et al. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal. 2009;7:13.
11. Joseph JV, Balasubramaniyan V, Walenkamp A, et al. TGF-β as a therapeutic target in high grade gliomas promises and challenges. Biochem Pharmacol. 2013;85:478–85.
12. Wick W, Naumann U, Weller M. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des. 2006;12:341–9.
13. Murphy PM. Chemokines and the molecular basis of cancer metastasis. New Engl J Med. 2001;345:833–5.
14. Moschovakis GL, Förster R. Multifaceted activities of CCR7 regulate T-cell homeostasis in health and disease. Eur J Immunol. 2012;42:1949–55.
15. Müller G, Lipp M. Shaping up adaptive immunity: the impact of CCR7 and CXCR5 on lymphocyte trafficking. Microcirculation. 2003;10:325–34.
16. Matsuda M, Ota S, Tanimura R, et al. Interaction between the amino-terminal SH3 domain of CRK and its natural target proteins. J Biol Chem. 1996;271:14468–72.
17. Ding Y, ShimadaY Maeda M, et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res. 2003;9:3402–12.
18. Liu FY, Safdar J, Li ZN, et al. CCR7 regulates cell migration and invasion through MAPKs in metastatic squamous cell carcinoma of head and neck. Int J Oncol. 2014;45:2502–10.
19. Suda K, Mizuuchi H, Murakami I, et al. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. Lung Cancer. 2014;85:147–51.
20. Cheng S, Han L, Guo J, et al. The essential roles of CCR7 in epithelial-to-mesenchymal transition induced by hypoxia in epithelial ovarian carcinomas. Tumour Biol. 2014;35:12293–8.
21. Nizard P, Ezan F, Bonnier D, et al. Integrative analysis of high-throughput RNAi screen data identifies the FER and CRKL tyrosine kinases as new regulators of the mitogenic ERK-dependent pathways in transformed cells. BMC Genomics. 2014;15:1169.
22. Copple BL. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor and transforming growth factor-beta-dependent mechanisms. Liver Int. 2010;30:669–82.
23. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 2010;21:89–92.
24. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.
25. Higgins DF, Kimura K, Bernhardt WM, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007;117:3810–20.